A randomized, double blind, placebo controlled, phase 2 study testing the use of combination multi-allergen food desensitization with dupilumab or omalizumab in multi-food allergic individuals

NIH RePORTER · NIH · U19 · $161,924 · view on reporter.nih.gov ↗

Key facts

NIH application ID: 10546082
Project number: 5U19AI104209-09
Recipient: STANFORD UNIVERSITY
Principal Investigator: R. Sharon Chinthrajah
Activity code: U19
Funding institute: NIH
Fiscal year: 2022
Award amount: $161,924
Award type: 5
Project period: 2013-07-01 → 2024-01-31